Better Buy: Inovio Pharmaceuticals vs. GlaxoSmithKline [The Motley Fool]
GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
US:NYSE Investor Relations:
gsk.com/en-gb/investors
Company Research
Source: The Motley Fool
In one corner, we have a small and scrappy biotech that has received a lot of attention this year as its stock skyrocketed. In the other corner, there's a big pharmaceutical company that's in a state of transition. It's a matchup betweenInovio Pharmaceuticals(NASDAQ:INOGlaxoSmithKlineNYSE:GSKBased on recent performance, Inovio would win in a knockout. Its shares have more than quadrupled in 00 so far, while GlaxoSmithKline stock is down year to date. But there's a lot more to the story for both drugmakers than their recent stock performances. Which stock is the better pick over the long run?Image source: Getty Images.The case for InovioThere's one big reason Inovio has been sizzling hot this year -- itsCOVID-9These earlier efforts enabled Inovio to rapidly create an experimental vaccine targeting COVID-9 earlier this year. The biotech began clinical testing of the vaccine earlier this month with the first patient dosed on April 6.Of course, there's still a long way to go for Inovio wi
Show less
Read more
Impact Snapshot
Event Time:
GSK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GSK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GSK alerts
High impacting GSK plc American Depositary Shares (Each representing two Ordinary Shares) news events
Weekly update
A roundup of the hottest topics
GSK
News
- GSK plc (NYSE: GSK) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- GSK plc (NYSE: GSK) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.MarketBeat
- Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapseBusiness Wire
- GSK plc (NYSE: GSK) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- GSK plc (NYSE: GSK) was downgraded by analysts at Deutsche Bank Aktiengesellschaft from a "buy" rating to a "hold" rating.MarketBeat
GSK
Sec Filings
- 12/20/24 - Form 6-K
- 12/20/24 - Form 6-K
- 12/16/24 - Form 6-K
- GSK's page on the SEC website